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women over 74, at £20,000/QALY threshold. Probabilities 
of cost-effectiveness are lower at younger ages, with mildly 
elevated cholesterol and over a 10-year time horizon. If con-
sumers bear the full cost of enriched spreads, NHS savings 
arise from reduced CVD events.
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Introduction
Raised total or low-density-lipoprotein cholesterol (LDL-c) 
is a major risk factor predisposing an individual to cardio-
vascular disease (CVD), which can be modified by various 
prevention programs, such as changes in diet. Plant ster-
ols and stanols (a saturated subgroup of sterols), hereafter 
referred to collectively as plant sterols, are plant equivalents 
of cholesterol with a very similar molecular structure [1]. 
They are found naturally in fruit, vegetables, nuts, seeds, 
grains, and legumes and prevent the absorption of choles-
terol into the bloodstream, but are unlikely to be consumed 
in sufficient quantities to reduce cholesterol levels [2–4]. 
Research has shown that adding plant sterols into the daily 
diet can substantially enhance the cholesterol-lowering 
effects of diet change [2–5]. Functional foods enriched with 
plant sterols, including margarine-type spreads, mayon-
naise and salad dressing, and dairy products (milk, yogurt, 
cheese), have been shown to achieve a beneficial effect on 
the serum lipid profile of the consumer [6].
Although the effectiveness of plant sterols in reducing 
LDL-c has been verified in a number of studies [2, 3, 7–13], 
evidence on whether use of plant sterols is a cost-effective 
Abstract This study appraises the effectiveness and 
cost-effectiveness of consumption of plant sterol-enriched 
margarine-type spreads for the prevention of cardiovascu-
lar disease (CVD) in people with hypercholesterolemia in 
England, compared to a normal diet. A nested Markov model 
was employed using the perspective of the British National 
Health Service (NHS). Effectiveness outcomes were the 
10-year CVD risk of individuals with mild (4–6 mmol/l) 
and high (above 6 mmol/l) cholesterol by gender and age 
groups (45–54, 55–64, 65–74, 75–85 years); CVD events 
avoided and QALY gains over 20 years. This study found 
that daily consumption of enriched spread reduces CVD 
risks more for men and older age groups. Assuming 50% 
compliance, 69 CVD events per 10,000 men and 40 CVD 
events per 10,000 women would be saved over 20 years. If 
the NHS pays the excess cost of enriched spreads, for the 
high-cholesterol group, the probability of enriched spreads 
being cost-effective is 100% for men aged over 64 years and 
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preventive strategy for reducing CVD risks is limited. To 
date, only four modeling studies have been identified but 
their findings may not be applicable to the United King-
dom (UK) context [14–17]. Three of these studies based 
their CVD risk estimations on the Framingham equation, 
which has been shown to overestimate CVD risks for the UK 
population and is no longer recommended by the National 
Institute of Health and Clinical Excellence (NICE) [18, 19]. 
Moreover, health states in some studies are simplified for the 
convenience of the analysis [14, 16]. Also, it is instructive to 
look at the cost-effectiveness separately for different age and 
gender groups and at different compliance levels.
The study reported in this paper used a nested Markov 
model to assess the effectiveness and cost-effectiveness of 
plant sterol-enriched functional foods for the prevention 
of CVD disease in the English population with hypercho-
lesterolemia, when compared to a normal diet (no plant 
sterol-enriched functional foods). The analysis takes the 
perspective of the British National Health Service (NHS), 
and considers costs borne by consumers for the purchase of 
functional foods. Health outcomes are represented by CVD 
events, mortality, and quality-adjusted life years (QALYs). 
Cost-effectiveness is defined by the NICE threshold of 
between £20,000 and £30,000 per QALY gained [20].
Methods
Model structure
A decision analytical model was used to synthesize epidemio-
logical, clinical, and economic data to appraise the effective-
ness and cost-effectiveness of plant sterol-enriched functional 
foods in the prevention of CVD in England. A nested Markov 
model structure, which allows the occurrence of both primary 
and secondary CVD events, was derived from a model used 
previously for a health technology assessment of the impact of 
statins [21]. All individuals start in the event-free (EF) health 
state. During each annual cycle of the model, individuals 
(depending on their risk) either remain EF or have a primary 
event and enter one of the event health states: stable angina, 
unstable angina, non-fatal myocardial infarction (MI), tran-
sient ischemic attack (TIA), non-fatal stroke, or death (either 
due to CVD or other causes). In each subsequent cycle, indi-
viduals in a non-fatal CVD event health state may move to a 
secondary event state, as shown in Table 1.
Population
The analysis focused on individuals aged 45 and above with 
baseline total cholesterol level ≥ 4 mmol/l [22]. Based on 
evidence in a recent meta-analysis, it was assumed that plant 
sterols are a primary prevention strategy and effective only 
for people in the EF state [4]. Hence, those with a history of 
CVD were excluded. The baseline cohort was drawn from 
the Health Survey for England (HSE) 2011, an annual survey 
conducted by the Health and Social Care Information Centre 
that uses random samples of the population living in private 
households to gather information about the nation’s health. 
In particular, the HSE 2011 focused on CVD and gathered 
information on an individual’s risk factors, including choles-
terol level, CVD history, and other relevant health and demo-
graphic variables. Data from the HSE 2011 have been used to 
model CVD risks in various health economic studies [23, 24].
Two clinical scenarios were considered: individuals with 
cholesterol levels between 4 and 6 mmol/l (mildly elevated 
cholesterol population) and those with cholesterol levels 
above 6 mmol/l (high-cholesterol population) [22]. For each 
scenario, the population was modeled separately by gender 
and age group (45–54, 55–64, 65–74, 75–85 years). The age 
range was determined by the QRISK2 function (www.qrisk.
org), which was used to predict CVD risks, and which only 
extends to 85 years.
Estimation of CVD risk and other‑cause mortality
The primary estimation of CVD risk for the study popula-
tion was based on the QRISK2 equation (QRISK2-2014). 
Recommended by NICE, QRISK2 is a new CVD risk 
Table 1  Model structure
Primary events Secondary events
From To From To
Event-free Event-free
Stable angina Stable angina Stable angina
Unstable angina
Non-fatal MI
Death
Unstable angina Unstable angina Post-unstable angina
Non-fatal MI
Death
Non-fatal MI Non-fatal MI Post non-fatal MI
Non-fatal MI
Non-fatal stroke
Death
TIA TIA Post-TIA
Non-fatal MI
Non-fatal stroke
Death
Non-fatal stroke Non-fatal stroke Post non-fatal stroke
Non-fatal MI
Non-fatal stroke
Death
Death
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prediction tool which provides a 10-year CVD risk estima-
tion for the UK population (www.qrisk.org) [25]. It is a vali-
dated tool and has been used in various clinical studies [18, 
19]. QRISK2 predicts CVD risks based on a wide range of 
risk factors including age, systolic blood pressure, smoking 
status, ethnicities, ratio of total serum cholesterol to high-
density lipoprotein, body mass index, family history of coro-
nary heart disease in first-degree relative, body mass index 
(BMI), Townsend deprivation score, treated hypertension, 
and diagnosis of rheumatoid arthritis, atrial fibrillation, type 
2 diabetes, and chronic renal disease.
The 10-year individual risk prediction provided by 
QRISK2 was converted to a 1-year risk for each gender and 
age subgroups. The conversion is based on published and 
validated algorithms [16, 26]. The QRISK2 tool indicates 
the probability of a CVD event occurring, but not the type 
of event. The distribution of types of events within groups, 
and the transition probabilities to model the number of peo-
ple moving from any particular health state to another over 
subsequent cycles, were based on the probabilities in a study 
conducted by Ward et al. [21]. The percentage of people 
dying from non-CVD causes was accounted for using age- 
and gender-specific mortality rates derived from Office of 
National Statistics data for 2015 [27]. Annual risks of non-
CVD deaths were estimated from the causes of death register 
by subtracting the fraction of deaths due to CVD causes 
from the total mortality.
Clinical effectiveness of plant sterols on cholesterol 
lowering
The dose–response relationship for the cholesterol-lowering 
effect of plant sterols has been explored in a number of meta-
analyses [2, 7, 9]. It is suggested that the LDL-c-lowering 
effect starts at intakes of 2–3 g/day with little additional 
benefit at higher intakes [1, 7]. It is also suggested that incor-
porating higher amounts of plant sterols into foods is techni-
cally unrealistic [28, 29]. Several health authorities include 
3 g/day plant sterols from enriched foods as part of their diet 
and lifestyle guidelines in the management of hypercholes-
terolemia [30, 31]. Therefore, this study used 3 g/day as the 
dose value for plant sterols in the model.
A literature search was undertaken to identify the clini-
cal effectiveness of plant sterols. A scientific opinion by the 
European Food Safety Authority (EFSA) suggested that an 
intake of plant sterols of 3 g/day (2.6–3.4 g) reduced the 
LDL-c levels effectively by 11.2–11.4% (95% CI 9.8–13.0), 
and that the minimum duration required to achieve the 
maximum effect is 2–3 weeks [4]. The conclusions of the 
effect size were consistent with other findings [2, 7]. The 
most recent clinical evidence (up to 2014) is provided by 
the meta-analysis of 129 studies by Ras et al. [9] conclud-
ing that intakes of approximately 3 g/day (plant sterols) led 
to an average LDL-cholesterol-lowering effect of 12%, and 
this was used as the basis for the modeling. In the absence 
of evidence for the time course of intervention effects, it was 
assumed that the protective effect of plant sterols continues, 
providing minimum intakes are maintained.
Impact of plant sterols on relative risk
The 10-year CVD risk was re-calculated for each individ-
ual in the study population using the QRISK2 assessment 
tool, and grouped by gender and age (as described above), 
assuming a 12% reduction to total cholesterol or LDL-c level 
caused by consuming 3 g/day of plant sterols. Relative risk 
(RR) was calculated as the ratio of the probability of a CVD 
event occurring with consumption of plant sterols to the 
probability of the event occurring in the non-exposed (nor-
mal diet) condition, for each gender and age group. Relative 
risks were used in the simulation, with standard errors of 
RRs taken into account to reduce parameter uncertainties. 
In this way, the difference in number of events between the 
functional food and normal diet conditions, and specifically 
the number of events avoided by sterol consumption, were 
identified.
Costs of health states and functional foods
One output of the model was annual numbers of individuals 
in different health states to which unit costs of treatment 
were applied. The cost of an event was included in the year 
in which it occurred, and a maintaining cost was applied 
in subsequent years. Costs of health states were largely 
obtained using 2014 NHS reference costs [32]. Where cost 
information was not available, costs from a published health 
technology evaluation of statins were used [21]. Information 
on the cost of health states can be found in Appendix 1.
Commonly available foods enriched with sterols include 
margarine-type spreads, yogurt, and milk. The analysis 
was based on spread, as this is the product that enables the 
required dose of plant sterols (3 g per day) to be consumed 
at the least cost. Margarine-type spreads are common items 
in the diet of the British population with median consump-
tion in adults around 40 g per day [33], which is sufficient to 
ensure an intake of 3 g of sterols (Appendix 2). The costs of 
products were obtained from the websites of three national 
supermarket chains in the UK in April 2015, with the super-
market’s own brand used for the non-sterol-enriched spread. 
Unit costs were the same across retailers for each product. 
Calculation of food costs can be found in Appendix 2.
Quality‑adjusted life years (QALYs)
Utility estimates for health states were derived from vari-
ous sources following a review of the literature that focused 
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on UK-based studies and use of the preference-based utility 
instrument, the EQ-5D, which is the recommended instru-
ment for measuring QALYs [34–36]. Health utilities used in 
the analysis can be found in Appendix 1. These utility values 
were applied to annual health states for individuals, and a 
mean value was calculated.
Main analysis
The baseline population was described using summary sta-
tistics. CVD risks and RRs for the normal diet group and 
plant sterol condition were compared. A cost-effectiveness 
analysis was then conducted from the NHS perspective. 
The price of spread enriched with plant sterols is higher 
than that of non-enriched spread and this may discourage 
purchases. Therefore, in the base case, it was assumed that 
the NHS would subsidize the cost difference between the 
supermarket’s own brand of non-enriched spread (£54.10 
pa) and the manufacturer-brand plant sterol spread (£111.04 
pa), i.e., £56.94 pa, for each of the 20 years of the modeling 
(Appendix 1). Two compliance rates—10 and 50%, based 
around pessimistic and ideal levels identified in a Canadian 
study—were explored [17]. The modeling was conducted 
over 20 years until the average age of the baseline cohort 
reached the life expectancy of the UK population (85 years). 
In line with NICE recommendations for health technology 
assessments, a discount rate of 3.5% was used for both costs 
and utilities [37].
The number of events avoided by consuming plant sterols 
over the modeling period was calculated by a determinis-
tic model. Incremental costs, incremental QALYs, and the 
incremental cost-effectiveness ratios (ICERs) were then cal-
culated for each gender and age group. Incremental costs 
from the plant sterol diet, compared to the normal diet, were 
calculated as the cost of the NHS subsidy for the spread 
over the 20-year period less any treatment cost savings from 
reduced CVD events. Incremental QALYs are the difference 
in QALYs between the plant sterol group and the normal 
diet group. ICERs show the cost per QALY gained when a 
diet enriched with plant sterols is followed, rather than a diet 
without the functional food. Uncertainty around point esti-
mates in the cost-effectiveness analysis was examined using 
probabilistic sensitivity analysis (PSA), and cost-effective-
ness acceptability curves (CEAC) were plotted. For each age 
and gender group, a second-order Monte Carlo simulation 
using the probabilistic parameters based on 5000 replica-
tions was carried out [26].
Sensitivity analysis
Four sets of sensitivity analyses were conducted. First, a 
one-way sensitivity analysis related to the assumed clinical 
efficacy of plant sterols was conducted using the estimated 
upper (13.3%) and lower (10.7%) limits of 95% confidence 
intervals around the average LDL reduction level of 12% in 
the paper [9]. Second, it was assumed that the NHS pays the 
full food costs, and the compliance level was 50%. Third, it 
was assumed that individuals were responsible for the full 
costs of the plant sterol-enriched spread (no NHS subsidy), 
and for this model a very pessimistic scenario of 5% compli-
ance was used [17]. Lastly, to align with the 10-year indi-
vidual risk protection provided by QRISK2, ICERs were 
recalculated for the base case (NHS pays the excess cost of 
sterol enriched margarine) over a 10-year time horizon, at 
50% compliance.
All analyses were carried out using STATA13 and Micro-
soft Excel 2013. Half cycle correction was used for costs 
and utilities. Detailed information of model parameters and 
distribution is shown in Appendix 3.
Results
Baseline description of study population
There were 1598 people with mildly elevated choles-
terol (4–6 mmol/l) and 640 with high cholesterol (above 
6 mmol/l) in the HSE 2011. The key risk factors are sum-
marized in Table 2. The mean BMI, systolic blood pressure, 
and total cholesterol/HDL cholesterol ratio was higher in the 
high-cholesterol group, which also contained a larger pro-
portion of women than the mild cholesterol group. Applying 
QRISK2, the average 10-year CVD risk for the mild-cho-
lesterol group is 12.27, and 12.85% for the high-cholesterol 
group.
Risks and events avoided
For both cholesterol groups, the 10-year CVD risks increase 
with age. The plant sterol group is associated with lower 
10-year CVD risks than the normal diet group at all ages 
Table 2  Baseline characteristics of modeled population by choles-
terol level
Mild-choles-
terol population 
(N = 1598)
High-choles-
terol population 
(N = 640)
Mean SD Mean SD
Age 59.40 10.42 60.46 9.91
Proportion of male 0.41 0.49 0.35 0.48
BMI 27.61 4.95 28.04 4.90
Systolic blood pressure (mmHg) 129.73 17.41 132.10 17.41
Total cholesterol (mmol/l)/HDL 
ratio (mmol/l)
3.98 1.38 4.51 1.53
10-year CVD risk 12.27 11.87 12.85 10.78
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(Fig. 1). Regarding relative risks, plant sterol-enriched func-
tional foods reduce CVD risk more in men than women, and 
in older age groups, compared to the younger ones (Table 3).
Using deterministic parameters, a diet including the rec-
ommended levels of plant sterols avoids 69 CVD events (59 
non-fatal and ten fatal CVD events) per 10,000 men and 
40 (33 non-fatal and seven fatal) per 10,000 women, aged 
45–85, at 50% compliance level, and 14 CVD events per 
10,000 men and eight CVD events per 10,000 women at 
10% compliance level.
Cost‑effectiveness—base case
The age- and gender-specific QALYs, costs, and ICERs 
(costs per QALY gained from sterol-enriched spread, com-
pared to normal spread) for different cholesterol populations 
over 20 years at 10 and 50% compliance levels, assuming the 
NHS pays the excess cost of the sterol-enriched product are 
shown in Table 4. The cost to the NHS of subsidizing sterol-
enriched spread is lower in men because more CVD events 
are avoided than in women. Accordingly QALY gains, which 
rise with compliance level and age, are also higher for men.
The ICERs (costs per QALY gained) are higher for 
mildly elevated cholesterol than for the high-cholesterol 
group. Hence, subsidizing sterol-enriched spread is more 
cost-effective at higher cholesterol levels. In both the 10 and 
50% compliance models, the cost per QALY gained is below 
the £20,000 threshold for men over 64 years and women 
over 74 years with high cholesterol; it is below the £30,000 
threshold for men over 54 and women over 64 (Table 4).
The cost-effectiveness acceptability curves (CEACs) for 
different age and gender groups at 10 and 50% compliance 
Fig. 1  Ten-year CVD risk for the mild- and high-cholesterol groups for the normal diet and plant sterol groups by age and gender
Table 3  RR by risk groups by 
age and gender Mild-cholesterol population High-cholesterol population
Male Female Male Female
Mean (%) 95% CI Mean 95% CI Mean (%) 95% CI Mean 95% CI
45–54 91.29 0.909, 0.917 94.00 0.938, 0.942 89.99 0.893, 0.907 92.81 0.923, 0.933
55–64 91.65 0.913, 0.920 93.93 0.937, 0.942 89.90 0.892, 0.906 93.30 0.930, 0.936
65–74 91.90 0.915, 0.923 93.62 0.934, 0.939 91.18 0.906, 0.918 93.03 0.927, 0.934
75–84 92.07 0.916, 0.926 94.00 0.937, 0.943 91.00 0.900, 0.920 93.42 0.930, 0.938
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levels for the high- and mild-cholesterol groups are shown 
in Figs. 2 and 3. For the high-cholesterol group, when the 
NHS pays the excess cost, the enriched spread is likely to 
be cost-effective for men over the age of 64, and women 
over 74, at the £20,000 threshold, and for men over 54 and 
women over 64 at the £30,000 threshold, at both the 10 and 
50% compliance levels. For the mild-cholesterol group, the 
probability that plant sterol-enriched spread is cost-effective 
for any age/gender group, compliance level or threshold is 
lower than for the high-cholesterol group.
Sensitivity analysis
Using the upper limit (13.3%) of the 95% confidence interval 
instead of the assumed mean LDL reduction (12%) from use 
of plant sterols, with 50% compliance, and the NHS covering 
the excess cost, did not affect the groups for which enriched 
spread was cost-effective. However, with the lower limit of 
the 95% confidence interval, the likelihood of plant sterol-
enriched spread being cost-effective is slightly increased for 
the mild-cholesterol group (Appendix 4).
When the assumption is adopted that the NHS is respon-
sible for the full costs of providing sterol-enriched spread, 
and the compliance rate is 50%, the plant sterol-enriched diet 
is only cost-effective for men over 64 with high cholesterol 
and between 75 and 85 with mild cholesterol, and if the cost-
effectiveness threshold is set at £30,000 per QALY gained. 
It is not cost-effective for women in any age group, or for 
either men or women at the lower threshold of £20,000 per 
QALY gained (Appendix 4).
If individuals are assumed to be responsible for the full 
cost of the sterol-enriched spread, the NHS realizes sav-
ings from reduced treatment costs due to fewer CVD events 
whilst incurring no charges for the products, even at a very 
pessimistic compliance rate of 5% (Appendix 4).
With a 10-year time horizon (instead of 20 years), at 50% 
compliance, sterol-enriched margarine becomes less cost-
effective for all groups (Appendix 4).
Discussion
Summary of main findings
This study is among the first to model CVD outcomes from 
consumption of plant sterol-enriched foods, and appraise 
cost-effectiveness within the British NHS for an adult popu-
lation with hypercholesterolemia. Multiple scenarios were 
considered involving varied cost-sharing arrangements 
between the consumer and the NHS (to affect consump-
tion), and different assumptions about levels of compli-
ance. Of several sterol-enriched foods available, the analy-
sis was based on margarine-type spreads because these are 
commonly consumed, and an efficacious ‘dose’ of sterols is 
achievable within average daily consumption levels. Moreo-
ver, enriched spread is the cheapest means of providing the 
required intake.
Under the assumption that the difference in cost to the 
consumer between sterol-enriched and normal spread is 
subsidized, then the sterol-enriched spread is likely to be 
cost-effective for men with hypercholesterolemia over the 
age of 64, and for women with hypercholesterolemia over 
74 years with the compliance level of 10 and 50% and the 
cost-effectiveness threshold of £30,000 per QALY gained. 
At the lower threshold of £20,000 per QALY gained, the 
subsidy is less likely to be cost-effective at lower age groups. 
Reducing the time horizon for the modeling diminishes 
the likelihood of sterol-enriched spread being cost-effec-
tive. Shifting the cost burden of the product to consumers 
increases the likelihood of cost-effectiveness. Ultimately, if 
consumers in the target groups bear the full cost, the NHS 
will maximally benefit from reduced CVD treatment costs. 
The other more costly sterol-enriched products are likely to 
be less cost-effective for the NHS.
Comparison to other studies
To date, only three other studies have evaluated the cost-
effectiveness of plant sterols [14, 16, 17]. A cost–benefit 
analysis of plant sterol-enriched low-fat margarine for cho-
lesterol reduction based on the German population found 
that the 10-year CVD risk and associated costs were signifi-
cantly lower for the plant sterol group compared with the 
normal diet group. A projection at the level of the German 
population led to a reduction of 117,000 CVD cases over 
10 years for the whole German population and a cost sav-
ing of €1.3 billion [14]. Similar results were demonstrated 
in Canada, where it was estimated that significant savings 
could be made annually for the publicly funded healthcare 
system if plant sterol-enriched food was approved for sale 
[17]. It has also been suggested that plant sterol-enriched 
spreads are potentially cost-effective in the prevention of 
CVD risks in adult men and in older women in Finland [16].
Limitations of the study
The results should be interpreted in light of the limitations 
of the study and the assumptions that were made. HSE only 
covers households in England so findings may not be more 
widely generalizable. Compliance levels were based on stud-
ies from Canada, but these may not reflect the consumption 
level of plant sterols in England. Complicating matters fur-
ther, the duration of the effects of plant sterols on reduc-
tion in LDL-c level is not clear. Whilst some studies found 
that the cholesterol-lowering effect is established within 
a few weeks, and is proved to remain stable for at least a 
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year [7, 8, 10], we have assumed a more enduring benefit. 
Research also shows that doses higher than 3 g/day could 
lead to negative side effects [8, 38, 39], but evidence on this 
is limited, and no effect has been allowed for. Furthermore, 
this study does not take account of potentially large inter-
individual variability in absorption and turnover of non-
cholesterol sterols that are increasingly under investigation. 
When these effects are better understood, they may influence 
screening policies and hence cost-effectiveness [40]. The 
study primarily adopted the perspective of the NHS. Societal 
effects associated with CVD are not included (productiv-
ity loss, family costs, social care). Consideration of these 
issues, however, would have increased the savings to the 
NHS and made sterol-enriched diets more likely to be cost-
effective. The data for risk calculations used in this study 
are mainly derived from HSE. However, it was not possible 
to take account of other lifestyle factors that might affect 
future risks and outcomes (e.g., exercise, health awareness, 
smoking, alcohol consumption). Similarly, it is possible that 
some subjects in the survey already consume sterols in some 
form or another, and since the extent of this was unknown, 
it could not be incorporated into the analysis. Also, the time 
horizon was set as 20 years, while QRISK2 is based on the 
estimation of 10-year risk.
The policy implications of the study
Pending results from randomized controlled trials, NICE 
does not recommend routine use of plant sterols and stanols 
for CVD prevention if the patient has already received treat-
ment [25], but focuses instead on promoting a more natu-
ral cardio-protective diet (low fat and sugar, whole grains, 
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fruit, vegetables, oily fish, nuts, seeds, legumes) and use of 
statins [41]. This position is supported by some scholars 
who have pointed out that plant sterols have not been shown 
to reduce clinical end points and suggest that prescription 
drugs should be preferred to stanol/sterol esters for lowering 
cholesterol except in borderline hypercholesterolemia [42]. 
Despite this, an increasing number of experts and health 
organizations recommend consuming plant sterols to reduce 
CVD risks, including the American and British Heart Asso-
ciations [31, 43]. Moreover, the European Commission has 
acknowledged the value of sterol-enriched foods for choles-
terol lowering through approval of health claims on some 
products [4, 6].
The findings from this study add weight to calls for the 
increased use of plant sterol-enriched functional food as a 
preventive strategy for people with hypercholesterolemia, 
and suggest that encouraging the consumption of plant 
sterol-enriched functional food is likely to bring cost sav-
ings to health systems, as well as improving patient out-
comes. In England, the annual cost of a subsidy equivalent 
to the excess cost of sterol-enriched spread (about £57 per 
subject in this study) is similar to the annual cost of many 
statins. Although subject to debate, a drawback that is raised 
regarding statins is that compliance is reduced because of 
side effects, and that adverse events may occur [44–47]. 
Such issues are less likely to be relevant to functional foods. 
Unlike statins, however, which are provided with doctor 
endorsement and on prescription, efforts may be needed to 
ensure that consumers are aware and motivated to use sterol-
enriched products and are able to understand the claims 
made on them. Under some circumstances, mass media 
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campaigns may be effective, but consideration needs to be 
given to costs and likely impact in policy deliberations [48].
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
Table 5  Cost- and health-utility values for health states
Health states Costs (£) Source Utility Source
EF 0 Ara et al. [36] 1.060–0.004*age Ara et al. [36]
Angina first year 684.00 NHS reference costs 2013/14 0.808 Lenzen et al. [49], Ara et al. [36]
Angina subsequent years 233.00 Ara et al. [38] (inflated to 2015) 0.9
Unstable angina first year 1428.50 NHS reference costs 2013/14 0.731 Goodacre et al. [35], Kim et al. [50]
Unstable angina subsequent years 233.00 Ara et al. [38] (inflated to 2015) 0.8
MI first year 1377.00 NHS reference costs 2013/14 0.7 Goodacre et al. [35], Lacey and 
Walters [51]MI subsequent years 233.00 Clarke et al. [57], 155 (inflated to 
2015)
0.8
TIA 1419.00 NHS reference costs 2013/14 1.060–0.004*age Aprile et al. [52], Ara et al. [36]
TIA subsequent years 373.00 Ara et al. [38] (inflated to 2015) 1.060–0.004*age
Stroke 4843.00 NHS reference costs 2013/14 0.5 Tengs and Lin [53], van Exel et al. 
[54], Leeds et al. [55]Stroke subsequent years 3055.00 Youman et al. [56] (inflated to 2015) 0.629
Table 6  Calculation of the food costs
The calculation of annual cost is based on 3 g/day intake and 365.25 days per year. One unit (bottle) of plant sterol yoghurt drink contains 2 g 
plant sterols, so the daily cost is based on a consumption of 2 units. There are currently two plant sterol enriched spreads available in the UK, 
and costs were based on the leading brand
Functional food Unit cost (£) Plant sterols Annual cost (£)
Plant sterol yoghurt drink 6 × 67.5 G (manufacturer’s brand) 3.78 2 g per bottle 460.2
Plant sterol yoghurt mini drink 6 × 100 ml (manufacturer’s brand) 3.5 2 g per bottle 426.13
Plant sterol Milk 1L (manufacturer’s brand) 1.39 3 g per 1 L mil2l 507.7
Plant sterol Light Spread 250 G (manufacturer’s brand) 1.9 18.75 g per 250 G spread 111.04
Non-sterol-enriched spread 500 G (supermarket’s own brand) 1.85 N/A 54.1
Appendix 2
See Table 6.
Appendix 3
See Table 7.
link to the Creative Commons license, and indicate if changes were 
made.
Appendix 1
See Table 5.
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Appendix 4
See Table 8.
Table 7  Parameters and distributions
Parameter distributions are consistent with Briggs et al. 2014
Base-line value Distribution Source
Annual CVD risks Derived from HSE 2011 using QRISK2 func-
tion
Log-normal Authors’ own
RR Age- and gender-specific RR Log-normal Authors’ own
Transition probabilities Age- and gender-specific transition probabilities Beta Derived from Ward et al. [21]
Costs of health states Cost for the first year and subsequent year of 
each health state was allowed
Gamma First-year costs were derived from NHS reference 
costs. Subsequent year costs were derived from 
Ward et al. [21]
Costs of the functional food Supermarket price in April, 2014 Deterministic Derived from supermarket websites in April, 
2014
Utility of health states Utilities of the first year and subsequent year of 
each health state was used in the analysis
Beta Derived from Ara et al., Ward et al. [21], 
D’Agostino et al. [34], Goodacre et al. [35], 
Lensen et al., Kim et al., Lacey et al.
Compliance level Varying compliance level at 50 and 100% for 
the main analysis.
Beta Derived from National Diet and Nutrition Survey
Discount rate 3.5% for both cost and utility Deterministic Derived from NICE technology appraisals meth-
ods guide 2013
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